An Independent Data Monitoring Committee (IDCM) has recommended that Amryt’s pivotal Phase III EASE trial for AP101 – a potential treatment for Epidermolysis Bullosa (EB) – should continue, raising hopes for a new therapy for the condition.
Read More
A surge in cell and gene therapy trials – an increase of 37% since 2017 – highlights the UK’s leading position as a developmental hub in the sector, says the Cell and Gene Therapy Catapult.
Read More
Cancer Research UK has announced that researchers have launched a clinical trial to develop a breath test that could help to find cancer early, when treatment is more likely to be effective.
Read More
Bristol-Myers Squibb has unveiled its intent to acquire Celgene in a deal worth $74 billion, in order to “create a premier innovative biopharma company”.
Read More
The National Institute for Health and Care Excellence (NICE) has approved Pfizer’s Xeljanz for adults with moderate to severe active ulcerative colitis.
Read More
